Login / Signup

Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.

Lisa A BeckDiamant ThaҫiMette DeleuranMarjolein de Bruin-WellerZhen ChenFaisal A KhokharMeng ZhangZafer E OzturkBrad Shumel
Published in: The Journal of dermatological treatment (2021)
NCT01949311.
Keyphrases
  • atopic dermatitis
  • high intensity
  • drug induced